Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03994510
Other study ID # UF 7681
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 18, 2020
Est. completion date September 2029

Study information

Verified date June 2022
Source University Hospital, Montpellier
Contact Déborah DUCASSE, MD, PhD
Phone (0)467338581
Email d-ducasse@chu-montpellier.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Borderline Personality Disorder (BPD) is a common psychiatric disorder occurring in 2 to 6% of the population. 70% of patients with BPD do at least one Suicide Attempt (SA) in their lives. It makes BPD the most related to SA condition. Negative interpersonal events are among the main stressor inducing a SA. Patients with BPD are characterized by emotional dysregulation, impulsivity (repeated parasuicidal and suicidal behaviors), and instability in interpersonal relationships. The feeling of shame related to this psychiatric disorder could be one of the causes of the high SA rate. In this study, patients with BPD will be follow-up during 5 years. The main objective is to study the propensity to feel shame as a predictor of SA. This include: - Study of shame propensity as a predictive factor of suicidal behavior - Identify homogeneous subgroups of patients with BPD based on SA, and overall functioning. - Identify biological markers predicting SA - Identify predictive and protective treatments (pharmacological and psychotherapeutic) for SA


Description:

This is a 5 years follow-up prospective study recruiting 688 patients. Schedule of the study : Inclusion period : 3 years Duration of follow-up of each patient : 5 years Estimated duration of the study : 8.5 years As part of the research, patients will be summoned annually for 5 years. The first visit (at baseline) is included in the usual care The follow-up visits are specifics to the research During the visits patients will complete self questionary and clinical interview. The organization of visits is as follows: - an inclusion visit lasting around 2 hours (clinical evaluation and then self-questionnaires) - a visit to 1 year, 2 years, 3 years, 4 years and 5 years (+/- 1 month) lasting approximately 1 hour 30 (clinical evaluation and passing of self-questionnaires) Genetic samples will be taken during the initial visit as well as during the visit to 5 years. They consist of: - A genetic collection consisting of a DNA library (3 Ethylene Diamine Triacetic Acid (EDTA) tubes of 6ml - 18 ml). - An off-genetics collection consisting of serum and plasma samples, (1 6 ml EDTA tube, 1 4 ml heparinized tube, 2 dry tubes of 5 ml each and 2 citrated tubes of 2.7 ml each - 25 , 4 ml).


Recruitment information / eligibility

Status Recruiting
Enrollment 688
Est. completion date September 2029
Est. primary completion date September 2029
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - To be over 18 - Clinical diagnosis of BPD using the SCID II (Structured Clinical Interview for DSM-IV-Text Reviewed Axis II Personality Disorders) - Having signed the informed consent - Able to understand the nature, the purpose and the methodology of the study - Able to understand and perform the clinical evaluations Exclusion criteria: - Deprived of liberty (by judicial or administrative decision) - Protected by law (guardianship) - Exclusion period in relation to another protocol - Not affiliated to a social security scheme

Study Design


Intervention

Other:
Clinical and biological assessments - a 5 Years follow-up
During each visit, a clinical evaluation will be carried out, as well as the filling of hetero-questionnaires and self-questionnaires. Two biological collections will be made: one during the inclusion visit, and the other during the last visit, 5 years after inclusion.

Locations

Country Name City State
France University Hospital of Montpellier Montpellier Hérault

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Montpellier INSERM 1061, " Neuropsychiatry: epidemiological and clinical research", Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Level of shame propensity Evaluation of the level of shame propensity will be measured using the Test of Self Conscious Affect (TOSCA) At enrollment
Primary Level of shame propensity Evaluation of the level of shame propensity will be measured using the Test of Self Conscious Affect (TOSCA) 1 year after enrollment
Primary Level of shame propensity Evaluation of the level of shame propensity will be measured using the Test of Self Conscious Affect (TOSCA) 2 years after enrollment
Primary Level of shame propensity Evaluation of the level of shame propensity will be measured using the Test of Self Conscious Affect (TOSCA) 3 years after enrollment
Primary Level of shame propensity Evaluation of the level of shame propensity will be measured using the Test of Self Conscious Affect (TOSCA) 4 years after enrollment
Primary Level of shame propensity Evaluation of the level of shame propensity will be measured using the Test of Self Conscious Affect (TOSCA) 5 years after enrollment
Primary Number of SA compared to the clinical data obtained in baseline The number of SA will be collected using Columbia Suicide Severity Rating Scale (C-SSRS) and compared to the clinical data obtained in baseline At enrollment
Primary Number of SA compared to the clinical data obtained in baseline The number of SA within the year will be collected using Columbia Suicide Severity Rating Scale (C-SSRS) and compared to the clinical data obtained in baseline 1 year after enrollment
Primary Number of SA compared to the clinical data obtained in baseline The number of SA within the year will be collected using Columbia Suicide Severity Rating Scale (C-SSRS) and compared to the clinical data obtained in baseline 2 years after enrollment
Primary Number of SA compared to the clinical data obtained in baseline The number of SA within the year will be collected using Columbia Suicide Severity Rating Scale (C-SSRS) and compared to the clinical data obtained in baseline 3 years after enrollment
Primary Number of SA compared to the clinical data obtained in baseline The number of SA within the year will be collected using Columbia Suicide Severity Rating Scale (C-SSRS) and compared to the clinical data obtained in baseline 4 years after enrollment
Primary Number of SA compared to the clinical data obtained in baseline The number of SA within the year will be collected using Columbia Suicide Severity Rating Scale (C-SSRS) and compared to the clinical data obtained in baseline 5 years after enrollment
Secondary Number of SA compared to the biological data obtained in baseline The number of SA will be collected using Columbia Suicide Severity Rating Scale (C-SSRS) and compared to the biological data obtained in baseline At enrollment
Secondary Number of SA compared to the biological data obtained in baseline The number of SA will be collected using Columbia Suicide Severity Rating Scale (C-SSRS) and compared to the biological data obtained in baseline 1 year after enrollment
Secondary Number of SA compared to the biological data obtained in baseline The number of SA will be collected using Columbia Suicide Severity Rating Scale (C-SSRS) and compared to the biological data obtained in baseline 2 years after enrollment
Secondary Number of SA compared to the biological data obtained in baseline The number of SA will be collected using Columbia Suicide Severity Rating Scale (C-SSRS) and compared to the biological data obtained in baseline 3 years after enrollment
Secondary Number of SA compared to the biological data obtained in baseline The number of SA within the year will be collected using Columbia Suicide Severity Rating Scale (C-SSRS) and compared to the biological data obtained in baseline 4 years after enrollment
Secondary Number of SA compared to the biological data obtained in baseline The number of SA within the year will be collected using Columbia Suicide Severity Rating Scale (C-SSRS) and compared to the biological data obtained in baseline 5 years after enrollment
Secondary Suicidal Ideation The number of suicidal ideation will be collected using Columbia Suicide Severity Rating Scale (C-SSRS). At enrollment
Secondary Suicidal Ideation The number of suicidal ideation will be collected using Columbia Suicide Severity Rating Scale (C-SSRS). 1 year after enrollment
Secondary Suicidal Ideation The number of suicidal ideation will be collected using Columbia Suicide Severity Rating Scale (C-SSRS). 2 years after enrollment
Secondary Suicidal Ideation The number of suicidal ideation will be collected using Columbia Suicide Severity Rating Scale (C-SSRS). 3 years after enrollment
Secondary Suicidal Ideation The number of suicidal ideation will be collected using Columbia Suicide Severity Rating Scale (C-SSRS). 4 years after enrollment
Secondary Suicidal Ideation The number of suicidal ideation will be collected using Columbia Suicide Severity Rating Scale (C-SSRS). 5 years after enrollment
Secondary Parasuicidal Behaviours The number of parasuicidal behaviours will be collected using Columbia Suicide Severity Rating Scale (C-SSRS). At enrollment
Secondary Parasuicidal Behaviours The number of parasuicidal behaviours will be collected using Columbia Suicide Severity Rating Scale (C-SSRS). 1 year after enrollment
Secondary Parasuicidal Behaviours The number of parasuicidal behaviours will be collected using Columbia Suicide Severity Rating Scale (C-SSRS). 2 years after enrollment
Secondary Parasuicidal Behaviours The number of parasuicidal behaviours will be collected using Columbia Suicide Severity Rating Scale (C-SSRS). 3 years after enrollment
Secondary Parasuicidal Behaviours The number of parasuicidal behaviours will be collected using Columbia Suicide Severity Rating Scale (C-SSRS). 4 years after enrollment
Secondary Parasuicidal Behaviours The number of parasuicidal behaviours will be collected using Columbia Suicide Severity Rating Scale (C-SSRS). 5 years after enrollment
Secondary Sick leave for a psychiatric condition The number of sick leaves, related to BPD, and their duration will be collected and reported on the case report form (CRF). At enrollment
Secondary Sick leave for a psychiatric condition The number of sick leaves, related to BPD, and their duration will be collected and reported on the case report form (CRF). 1 year after enrollment
Secondary Sick leave for a psychiatric condition The number of sick leaves, related to BPD, and their duration will be collected and reported on the case report form (CRF). 2 years after enrollment
Secondary Sick leave for a psychiatric condition The number of sick leaves, related to BPD, and their duration will be collected and reported on the case report form (CRF). 3 years after enrollment
Secondary Sick leave for a psychiatric condition The number of sick leaves, related to BPD, and their duration will be collected and reported on the case report form (CRF). 4 years after enrollment
Secondary Sick leave for a psychiatric condition The number of sick leaves, related to BPD, and their duration will be collected and reported on the case report form (CRF). 5 years after enrollment
Secondary Hospitalization for a psychiatric condition The number of hospitalization, related to BPD, and their duration will be collected and reported on the case report form (CRF). At enrollment
Secondary Hospitalization for a psychiatric condition The number of hospitalization, related to BPD, and their duration will be collected and reported on the case report form (CRF). 1 year after enrollment
Secondary Hospitalization for a psychiatric condition The number of hospitalization, related to BPD, and their duration will be collected and reported on the case report form (CRF). 2 years after enrollment
Secondary Hospitalization for a psychiatric condition The number of hospitalization, related to BPD, and their duration will be collected and reported on the case report form (CRF). 3 years after enrollment
Secondary Hospitalization for a psychiatric condition The number of hospitalization, related to BPD, and their duration will be collected and reported on the case report form (CRF). 4 years after enrollment
Secondary Hospitalization for a psychiatric condition The number of hospitalization, related to BPD, and their duration will be collected and reported on the case report form (CRF). 5 years after enrollment
Secondary The need to emergency psychiatric consult The number of emergency visit related to BPD, will be collected and reported on the case report form (CRF). At enrollment
Secondary The need to emergency psychiatric consult The number of emergency visit related to BPD, will be collected and reported on the case report form (CRF). 1 year after enrollment
Secondary The need to emergency psychiatric consult The number of emergency visit related to BPD, will be collected and reported on the case report form (CRF). 2 years after enrollment
Secondary The need to emergency psychiatric consult The number of emergency visit related to BPD, will be collected and reported on the case report form (CRF). 3 years after enrollment
Secondary The need to emergency psychiatric consult The number of emergency visit related to BPD, will be collected and reported on the case report form (CRF). 4 years after enrollment
Secondary The need to emergency psychiatric consult The number of emergency visit related to BPD, will be collected and reported on the case report form (CRF). 5 years after enrollment
Secondary Major depressive episodes The number of major depressives episodes and the measure of the depression intensity will be collected using the Inventory of Depressive Symptomatology (IDS-C30). At enrollment
Secondary Major depressive episodes The number of major depressives episodes and the measure of the depression intensity will be collected using the Inventory of Depressive Symptomatology (IDS-C30). 1 year after enrollment
Secondary Major depressive episodes The number of major depressives episodes and the measure of the depression intensity will be collected using the Inventory of Depressive Symptomatology (IDS-C30). 2 years after enrollment
Secondary Major depressive episodes The number of major depressives episodes and the measure of the depression intensity will be collected using the Inventory of Depressive Symptomatology (IDS-C30). 3 years after enrollment
Secondary Major depressive episodes The number of major depressives episodes and the measure of the depression intensity will be collected using the Inventory of Depressive Symptomatology (IDS-C30). 4 years after enrollment
Secondary Major depressive episodes The number of major depressives episodes and the measure of the depression intensity will be collected using the Inventory of Depressive Symptomatology (IDS-C30). 5 years after enrollment
Secondary Global functioning The Global functioning will be measured using the Functioning Assessment Short Test (FAST). At enrollment
Secondary Global functioning The Global functioning will be measured using the Functioning Assessment Short Test (FAST). 1 year after enrollment
Secondary Global functioning The Global functioning will be measured using the Functioning Assessment Short Test (FAST). 2 years after enrollment
Secondary Global functioning The Global functioning will be measured using the Functioning Assessment Short Test (FAST). 3 years after enrollment
Secondary Global functioning The Global functioning will be measured using the Functioning Assessment Short Test (FAST). 4 years after enrollment
Secondary Global functioning The Global functioning will be measured using the Functioning Assessment Short Test (FAST). 5 years after enrollment
Secondary Life Quality The Life Quality will be measured using the Satisfaction With Life Scale (SWLS). At enrollment
Secondary Life Quality The Life Quality will be measured using the Satisfaction With Life Scale (SWLS). 1 year after enrollment
Secondary Life Quality The Life Quality will be measured using the Satisfaction With Life Scale (SWLS). 2 years after enrollment
Secondary Life Quality The Life Quality will be measured using the Satisfaction With Life Scale (SWLS). 3 years after enrollment
Secondary Life Quality The Life Quality will be measured using the Satisfaction With Life Scale (SWLS). 4 years after enrollment
Secondary Life Quality The Life Quality will be measured using the Satisfaction With Life Scale (SWLS). 5 years after enrollment
See also
  Status Clinical Trial Phase
Recruiting NCT04856449 - DBT Skills Plus EMDR for BPD and Trauma N/A
Active, not recruiting NCT04587518 - Five Factor Model Treatment for Borderline Personality Disorder N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Completed NCT03677037 - The Short-Term MBT Project Phase 3
Not yet recruiting NCT05989529 - Delving Into Borderline Personality Disorder Clinical Trial Experiences
Completed NCT02518906 - Evaluation of AIT Study N/A
Completed NCT02068326 - MBT in Groups for Adolescents With BPD or Subthreshold BPD Versus TAU - the M-GAB Randomized Controlled Trial N/A
Recruiting NCT04296604 - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations N/A
Completed NCT02108990 - Acetaminophen and Social Processes Phase 2
Terminated NCT02149823 - Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Phase 1
Completed NCT01635556 - Evaluation of a Modified Dialectical Behavior Therapy Program N/A
Not yet recruiting NCT01683136 - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder N/A
Completed NCT02988037 - Adapted Dialectical Behaviour Therapy for Adolescents With Deliberate Self-Harm: A Pre-post Observational Study N/A
Completed NCT02397031 - Mindfulness and Interpersonal Effectiveness Skills in Borderline Personality Disorder N/A
Terminated NCT01103180 - Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder Phase 2
Terminated NCT01212588 - Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD) Phase 2
Terminated NCT00539188 - N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD Phase 2
Recruiting NCT05398627 - Neurofeedback for Borderline Personality Disorder N/A
Recruiting NCT06005129 - Personality Change Study for Borderline Personality Disorder N/A
Recruiting NCT06406972 - Brief Admission by Self-referral for Individuals With Self-harm: Effects on Compulsory Care